NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Nantong Guangyuan Chemical GYC

Published 12 Nov 2026. 30-page investigative report on who is behind Nantong Guangyuan Chemical GYC: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Nantong Guangyuan Chemical GYC is a product-specific case, not a blanket pass. Across 54 Finnrick lab tests, the record is 48 pass / 6 fail, an 89% overall pass rate. Retatrutide is the strongest authenticated GYC signal and Tirzepatide remains usable but imperfect; Cagrilintide and Semaglutide are materially weaker.

The bigger risk is channel control. Public records support a real Nantong-based trading operation and an official COA tracker, but the open-web buying path is polluted by lookalikes. The report documents a live ggpeps.net storefront that presents as GYC, uses non-official contact anchors, and routes purchase actions to Oath Research’s shop instead of an authenticated GYC checkout.

That clone is wrapped in a manufactured trust layer: review and “verification” sites share a NICENIC/Cloudflare pattern, cloned review sets change mechanically, and peptide-award claims trace to GL Biochem rather than GYC. Oath’s Arizona ownership chain is documented in a federal complaint; GYC’s natural-person ownership remains unresolved because Chinese registry access was blocked.

The practical read is channel-specific: authentic GYC Retatrutide or Tirzepatide may deserve consideration after batch verification, while clone-sourced material and the weaker Cagrilintide/Semaglutide record require a much higher burden of proof.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 4 tested products
  • Source-code capture and live-click evidence for the ggpeps.net to oath.shop purchase redirect
  • NICENIC/Cloudflare network map covering review domains and clone storefronts
  • Side-by-side credential diff tracing clone award claims to GL Biochem records
  • Oath Research complaint ownership chain and unresolved Chinese registry trail
  • Official-channel, Discord, Telegram and COA-verification checklist

Risk assessment

  • Impersonation and payment-loss risk — high: ggpeps.net and related clone channels impersonate GYC; live Add to Cart and checkout actions route to oath.shop, a different vendor, while community reports describe payments taken with no packages sent.
  • Fabricated verification and review-manipulation risk — high: PeptideMeter, Medutest, VendorInvestigate, CompoundTalk and sibling sites share infrastructure and publish recycled signals; ggpeps.net review sets show mechanical replacement patterns.
  • Fabricated credential and manufacturing-claim risk — high: ggpeps.net presents GL Biochem awards and unverified GMP/ISO/direct-manufacturer claims as GYC or parent-company credentials; no public record ties GYC to GL Biochem.
  • Product-specific quality risk — Cagrilintide and Semaglutide — high: Cagrilintide 4 tests (3 pass / 1 fail, 58.7%) and Semaglutide 3 tests (1 pass / 2 fail, 61.9%) are materially weaker than GYC's Retatrutide/Tirzepatide record.
  • Product-specific quality risk — Tirzepatide and Retatrutide — medium: Tirzepatide 25 tests (23 pass / 2 fail, 88.06%) and Retatrutide 22 tests (21 pass / 1 fail, 90.07%) are usable only for authenticated GYC material and still include recorded failures.
  • Channel-authentication instability — medium: The official storefront is login-gated, Discord/email anchors have rotated, and GYC is Archived/Inactive on GLP-1 Forum while promotions continued; buyers must authenticate through current official channels and COA lookup.